

Synthesis, Spectroscopic and Antimicrobial Investigations of Scandium(III) Complexes with Four Kinds of Sulfa Drugs

Moamen S. Refat^{1,2*}, Abeer A. El-Habeeb³

1. Chemistry Department, Faculty of Science, Taif University, P. O. Box 888, Al-Hawiah, Taif 21974, Saudi Arabia
2. Department of Chemistry, Faculty of Science, Port Said, Port Said University, Egypt
3. College of Science, Princess Nourah Bint Abdulrahman University, Department of Chemistry, KSA

Abstract Herein, this article was focused on the synthesis and discussed the spectroscopic characterizations of four new scandium(III) sulfa-drug complexes. The nomenclature and symbols of these drugs were sulfadimidine (sulp-1), sulfanilamide (sulp-2), sulfamethoxazole (sulp-3) and sulfadiazine (sulp-4). The microanalytical and spectroscopic analyses which utilized in this study were micro-analyses, magnetic, FT-IR, UV-Vis techniques. The mid infrared spectra deduced that the four sulfa-drug chelates acts as a bidentate chelates with scandium(III) ion via two nitrogen atoms of $-\text{NH}_2\text{-Ar}$ and $-\text{NH-SO}_2$ groups. Also, the FTIR spectra of Sc^{3+} complexes referred to the existed of new medium weak bands in the range of $500\sim 400\text{ cm}^{-1}$ due to stretching vibration bands of $\nu(\text{M-N})$. The elemental analysis technique confirmed the 1 : 2 stoichiometry between Sc^{3+} ions and sulp ligand with molecular formula $[\text{Sc}(\text{sulp})_2(\text{Cl})_2] \cdot \text{Cl}$. At room temperature, the results of magnetic measurements for the $\text{Sc}(\text{III})$ complexes indicated that all of the synthesized complexes have a diamagnetic character with octahedral configuration. The electronic spectra of the free sulfa-drug ligands shows band at 275 and 310 nm which are intraligand charge transfer band. The electronic absorption spectra of the Sc^{3+} complexes were recorded using DMSO solvent. The spectra of complexes display bands within 275~388 nm, which attributed to $\pi-\pi^*$, $n-\pi^*$ and charge-transfer M-L_{CT} electronic transitions, which strongly favors the octahedral geometry around $\text{Sc}(\text{III})$ metal ions. ^1H NMR spectra of complexes referred to the downfield proton shifts of the $-\text{NH}_2$ and NHSO_2 groups, which supported the place of coordination. The half maximal inhibitory concentration (IC_{50}) of the Sc^{III} complexes was assessed against the human hepato cellular carcinoma (HepG-2) tumor cell line.

Keywords Sulfa-drugs; Sc^{III} ; Spectroscopic; Chelation; Nano-particles; Antimicrobial

中图分类号: O433 文献标识码: A DOI: 10.3964/j.issn.1000-0593(2020)03-0985-06

Introduction

Sulfonamides $-\text{NHSO}_2$ received much attention because of their tendency to attached with different drugs as a medicinal drugs against bacterial infections and serious diseases in humans^[1-2]. Although sulfonamides are old drugs, they are still considered useful in some therapeutic areas especially in the case of eye infections as well as urinary, gastrointestinal

infections^[3-4] and the complex composition of metal ions and sulfa-drugs themselves constitute an important area of research^[5]. Moreover, sulfa drugs and their metal complexes have many applications, as well as antibacterial activity such as diuretics, anti-glaucoma or antiepileptic, among other things^[6], such as antifungal activity^[7], and in many cases, metal compound activity is much better than ligand alone^[7]. Fox et al.^[8], was discussed number of different metal sulfa drug complexes and their antimicrobial activities. Silver(I),

Received: 2019-08-31; accepted: 2019-12-26

* Corresponding author e-mail: msrefat@yahoo.com

zinc(II) and cerium(III) sulfadiazine complexes were synthesized, characterized and they were found a distinguish properties as a burn treatment^[9]. Srivastava et al.^[10], have been reported the synthesis and spectroscopic investigations of the coordination between sulphaguanidine ligand and different metal ions like Fe²⁺, Cu²⁺, Cd²⁺, V⁴⁺, Mo⁵⁺, Pb²⁺, Se⁴⁺, and Sn⁴⁺ ions have been synthesized and investigated. The rare earth mixed ligand complexes with sulfamethoxy as a primary and pyridazine as a secondary chelates were synthesized and spectroscopically studied^[11], while Gupta and Jha^[12] have been characterized an antimony(III) complexes with different kinds of sulfa drugs^[13]. The complexation between two sulfa drugs (sulphisoxazole and sulfamethoxazole) ligands and first series of transition metal ions have been synthesized and characterized by Kanagaraj and Rao authors^[13].

In literature survey, our group were prepared and discussed some of transition (Mn(II), Hg(II), Cr(III), ZrO(II), VO(II)) and rare earth metal (Y(III), Ce(III), Gd(III), Nd(III), Tb(III), Er(III)) complexes with sulfasalazine drug ligand^[14]. These complexes were spectroscopy

characterized and biologically screened against bacteria, fungi and cancer cell lines. In literature survey, there is no work appears to have been done on the chelation between sulfa-drug with Sc^{III} ion. It should be noted that the medicinal properties of scandium metal is now recognized, and the scandium has been of interest because of its possible use as an adjunct to ⁶⁷Ga survey of cancer patients^[15]. It was therefore thought to be useful to assemble some Sc³⁺ sulfa drugs for the first time. The main objective of this work is to prepare and spectroscopic characterize scandium complexes (III) with sulph-1, sulph-2, sulph-3 and sulph-4 sulfa drugs and to determine coordination sites, antimicrobial and anti-cancer assessment.

1 Experimentals

1.1 Chemicals

There are pure grade and used as received, the name of chemicals, exporting company and their purpose can be listed as follows:

| Chemicals | Company | Purpose |
|-----------------------|-----------------------------|---------------------|
| Sulfadimidine | | |
| Sulfanilamide | | |
| Sulfamethoxazole | Sigma-Aldrich, USA | Chemical Synthesis |
| Sulfadiazine | | |
| ScCl ₃ | | |
| DMSO | Sigma-Aldrich, USA | Chemical analysis |
| Crystal violet | Sigma (St. Louis, Mo., USA) | |
| Trypan blue dye | | |
| Fetal Bovine serum | | |
| EMEM | | |
| RPMI-1640 | Lonza Group AG, Switzerland | Biological analysis |
| HEPES buffer solution | | |
| L-glutamine | | |
| Gentamycin | | |
| 0.25% Trypsin-EDTA | | |

1.2 Synthesis of scandium(III) sulfa-drug complexes

A 1.0 mmol (152 mg) of ScCl₃ and 2.0 mmol from sulfadimidine (557 mg), sulfanilamide (345 mg), sulfamethoxazole (507 mg), or sulfadiazine (501 mg) were separately dissolved in methanol (25 mL), then mixed and refluxed for 6 hrs, yielding a white solution which was concentrated and left for three days yielding a white precipitate then filtered and washed with hot methanol solvent. The resulting solid precipitates were dried in a dessicator for seven days to afford the desired solid complexes. The elemental, physical and micro-analytical data are summarized in Table 1.

1.3 Instrumentals

1.3.1 Instrument

Perkin Elmer CHN 2400; Jenway 4010 conductivity meter; Bruker FTIR Spectrophotometer; UV2 Unicam UV/Vis Spectrophotometer; Magnetic balance, Sherwood Scientific, Cambridge, England, at Temp 25 °C; Varian mercury VX-300 NMR Spectrometer.

1.3.2 Measurement

Contents C, H and N; Electrolytic or non-electrolytic character; IR measurements; Electronic spectra; Magnetic moments; ¹H-NMR spectrum.

1.4 Antimicrobial and anticancer assessments

Antimicrobial activity was performed dependent on modified Kirby-Bauer disc diffusion method^[16]. The tested species of bacteria and fungi are Escherichia coli, Pseudomonas

aeruginosa, *Bacillus subtilis*, *Staphylococcus aureus*, *Aspergillus flavus* and *Candida albicans*. The cytotoxicity of sam-

ples was screened against human Hepatocellular carcinoma (HepG-2) using viability assay^[17].

Table 1 Elemental and physical data of sulfa drugs scandium(III) complexes

| Complexes | Color | Content[(calculated) found] | | | | $\Delta_M /$ ($\Omega^{-1} \cdot \text{cm}^2 \cdot \text{mol}^{-1}$) | Yield /% |
|--|-------|-----------------------------|--------|---------|--------|---|-------------|
| | | %C | %H | %N | %M | | |
| [Sc(sulp-1) ₂ (Cl) ₂] · Cl, (1) | white | (40.72) | (3.99) | (15.83) | (6.35) | 40 | 63 |
| | | 40.34 | 3.78 | 15.69 | 6.21 | | |
| [Sc(sulp-2) ₂ (Cl) ₂] · Cl, (2) | white | (29.07) | (3.25) | (11.30) | (9.07) | 45 | 64 |
| | | 29.02 | 3.19 | 11.22 | 9.02 | | |
| [Sc(sulp-3) ₂ (Cl) ₂] · Cl, (3) | white | (36.51) | (3.37) | (12.77) | (6.83) | 38 | 60 |
| | | 36.25 | 3.32 | 12.63 | 6.71 | | |
| [Sc(sulp-4) ₂ (Cl) ₂] · Cl, (4) | white | (36.85) | (3.09) | (17.19) | (6.90) | 34 | 62 |
| | | 36.81 | 3.04 | 17.03 | 6.64 | | |




Fig. 1 Suggested structural formulas of Sc^{III} sulf-drug complexes

2 Results and discussion

2.1 Structural characterization of the Sc(III) sulfa-drug complexes

2.1.1 Stoichiometric and molar conductance results

The micro analytical data of the synthesized Sc³⁺ complexes are in agreement with 1 : 2 stoichiometry (Sc : sulp) as referred in experimental section. The white scandium(III) complexes are stable in static air with highly melting points (>300 °C), insoluble in H₂O and slightly soluble in DMSO

and DMF solvents with gently heating. The Sc^{III} complexes have a slightly electrolytic nature^[18] with molar conductance values within 34~45 $\Omega^{-1} \cdot \text{cm}^2 \cdot \text{mol}^{-1}$ range, this is due to the presence of one chloride ion outside the coordination sphere. The Sc^{III} complexes have a diamagnetic state with an octahedral geometry^[19] as shown in Fig. 1.

2.1.2 Infrared spectral assignments

FTIR spectra of Sc^{III} sulfa-drug complexes are displayed in Fig. 2(a) and the distinguish peaks are assigned in Table 2. Regarding free sulfa-drug ligands, there are observed bands at 3 479~3 423 and 3 379~3 343 cm^{-1} due to asymmetric and symmetric stretching vibratioo bands —(NH) of aniline group —NH₂^[20]. The bands presence at 3 290~3 242 cm^{-1} are assigned to —NH stretching vibration of (SO₂NHR) sulfonamide group^[20]. Concerning of Sc^{III} complexes, the ν_{as} (NH) of aniline group is existed at 3 461~3 420 cm^{-1} and the ν_{s} (NH) band is exhibit at 3 370~3 340 cm^{-1} . These shifts to lower frequencies are due to the involved in coordination toward Sc^{III} ions. Moreover, tie bending —(NH₂) vibration of —NH₂ group take place at 1 652~1 619 cm^{-1} for the free sulfa-drugs compounds is shifted to lower wavenumbers after complexity with Sc^{III} ions to became at 1 611~1 645 cm^{-1} . On the other hand, the —NH band of —SO₂NH group was exhibited at 3 290~3 242 cm^{-1} in case of free sulfa-drugs, this is shifted to lower wavenumbers by 5~24 cm^{-1} upon complexation^[20]. These FTIR results are supported the involvement of both —NH₂ and —NH groups in the coordination toward scandium(III) ions. The strong-to-very strong bands placed at 1 325~1 303 cm^{-1} and 1 165~1 145 cm^{-1} in the free sulfa-drugs are attributed to asymmetric and symmetric stretching vibrations of the —SO₂ sulfonyl group, respectively. In case of Sc(III) complexes, it's found that, these presented bands are located at the same place or shifted to slightly higher wavenumbers. These data reveal that the sulfonyl group doesn't involved in the coordination^[20]. The absent of any bands in case of Sc(III) complexes at ~3 500 cm^{-1} are due to absence of

coordinated or uncoordinated water molecules, so the complexes are found in the anhydrous form. The new medium-to-weak




Fig. 2(a) FTIR spectra of Sc^{III} sulfa-drug complexes

a; Sulp-1; b; Sulp-2; c; Sulp-3; d; Sulp-4

bands observed in the infrared spectra for all Sc^{III} complexes within the range of 500~400 cm⁻¹ are attributed to $\nu(M-N)$ bands [see Fig. 2(b)]^[20].




Fig. 2(b) Far-IR spectra of Sc^{III} sulfa-drug complexes

Table 2 FT-IR spectral frequencies (cm⁻¹) of sulfa-drugs and its Sc^{III} complexes

| Compounds | Anilino group ($-\text{NH}_2$) | | | Sulfonamido group ($-\text{SO}_2\text{NH}$) | | |
|-----------|----------------------------------|-----------------------------|-----------------------|---|--------------------------------|-------------------------------|
| | $\nu_{\text{as}}(\text{NH})$ | $\nu_{\text{s}}(\text{NH})$ | $\delta(\text{NH}_2)$ | $\nu(\text{NH})$ | $\nu_{\text{as}}(\text{SO}_2)$ | $\nu_{\text{s}}(\text{SO}_2)$ |
| sulp-1 | 3 442 | 3 343 | 1 640 | 3 242 | 1 303 | 1 147 |
| sulp-2 | 3 479 | 3 374 | 1 630 | 3 269 | 1 312 | 1 148 |
| sulp-3 | 3 467 | 3 379 | 1 619 | 3 290 | 1 305 | 1 145 |
| sulp-4 | 3 423 | 3 355 | 1 652 | 3 258 | 1 325 | 1 156 |
| Complex 1 | 3 438 | 3 340 | 1 635 | 3 235 | 1 303 | 1 146 |
| Complex 2 | 3 461 | 3 369 | 1 626 | 3 245 | 1 313 | 1 145 |
| Complex 3 | 3 460 | 3 370 | 1 611 | 3 285 | 1 311 | 1 157 |
| Complex 4 | 3 420 | 3 345 | 1 645 | 3 250 | 1 325 | 1 155 |


2.1.3 Electronic and magnetic measurements

An electronic spectra of sulfa-drugs ligands and their Sc (III) complexes were scanned within 200~800 nm range. These spectra have two absorption bands at 275 and 310 nm that attributed to $\pi-\pi^*$ transition of the aromatic rings^[21] and $n-\pi^*$ transition of the anilino $-\text{NH}_2$ and sulfonamido $-\text{NHSO}_2$ groups. The electronic spectra of the four scandium (III) complexes have different electronic transitions of the $\pi-\pi^*$, $n-\pi^*$ and charge-transfer M-LCT are presence at (277, 315, 388 nm), (275, 295, 309 and 372 nm), (276, 281, 297, 298 and 312 nm) and (277, 312, 322 and 326 nm) for the Sc^{III} complexes of sulp-1, sulp-2, sulp-3 and sulp-4, respectively. These bands have be relocate rather than free ligands because of binding to the central metal ions. In case of octahedral statement of Sc(III) complex, the charge-transfer transition band is often occur at low energy^[21]. The scandium (III) sulfa-drug complexes have μ_{eff} within the range of 0.43~0.69 BM, this is assigned to a diamagnetic octahedral geometry^[19].

2.1.4 ¹H NMR assignments

¹H-NMR spectra of the sulp-3 drug and its $[\text{Sc}(\text{sulp-3})_2(\text{Cl})_2] \cdot \text{Cl}$ complex, were scanned. In Table 3, the signals

of sulp-3 drug and its Sc^{III} complex with significant shifts are assigned. These results supported the site of coordination between the sulp-3 ligand and Sc^{III} metal ions. ¹H signals of sulp-3 spectrum (scheme 1) comparing with the spectrum of scandium(III) complex, it is clearly that they are relevant displacement shifted towards downfield when the sulp-3 ligand is coordinated to Sc(III), especially those assigned to 2H; (NH₂), that is presented at 6.10 ppm for the free ligand, and at 6.45 ppm in the complex and ¹H; (NHSO₂) from 10.95 to 11.00, supported that the sulp-3 ligand is chelated *via* the NH₂ anilino nitrogen atom and the $-\text{NH}$ sulfonamido nitrogen groups.



Scheme 1 Numerical protons of sulp-3 free ligand

2.1.5 Antimicrobial and Anticancer assessments

The antimicrobial activities of the free sulfa-drugs com-

Table 3 $^1\text{H-NMR}$ proton signals of the sulph-3 ligand and $\text{Sc}(\text{III})$ complex

| δ ^1H | A | B | C | D | E | F |
|-------------------------|-------|------|------|------|------|------|
| sulp-3 | 10.95 | 7.49 | 6.60 | 6.11 | 6.10 | 2.29 |
| $\text{Sc}(\text{III})$ | 11.00 | 7.54 | 6.70 | 6.10 | 6.45 | 2.29 |

plexes (sulp-1, sulp-2, sulp-3 and sulp-4) and their $\text{Sc}(\text{III})$ complexes have biologically assessed *in vitro* against bacteria and fungi species (*Escherichia coli*, *Pseudomonas aeruginosa*, *Bacillus subtilis*, *Staphylococcus aureus*, *Aspergillus flavus* and *Candida albicans*). The zones of inhibition produced by the test compounds are summarized in Table 4. It is observed that:

(1) $[\text{Sc}(\text{sulp-1})_2(\text{Cl})_2] \cdot \text{Cl}$ complex has a significant inhibition against *E. coli*, *B. subtilis*, *S. aureus* and *Candida albicans* in comparable with free sulp-1 drug.

(2) $[\text{Sc}(\text{sulp-2})_2(\text{Cl})_2] \cdot \text{Cl}$ complex has a significant inhibition against *P. aeruginosa*, *B. subtilis*, *S. aureus*, *A. flavus* and *Candida albicans* in comparable with free sulp-2 drug.

(3) $[\text{Sc}(\text{sulp-3})_2(\text{Cl})_2] \cdot \text{Cl}$ complex has a significant inhibition against *E. coli*, *B. subtilis*, *S. aureus*, *Aspergillus*

flavus and *Candida albicans* in comparable with free sulp-3 drug.

(4) $[\text{Sc}(\text{sulp-4})_2(\text{Cl})_2] \cdot \text{Cl}$ complex has a significant inhibition against *E. coli*, *P. aeruginosa*, *B. subtilis*, *S. aureus* and *Candida albicans* in comparable with free sulp-4 drug.

On complexity, the polarity of the metal ion is greatly reduced due to the partial sharing of a positive charge of the metal ion interfering with the donor groups. Increased lipophilicity promote the penetration of complexes in lipid membranes and block mineral binding sites on microorganism enzymes^[22].

In vitro cytotoxicity assessment of the $[\text{Sc}(\text{sulp-4})_2(\text{Cl})_2] \cdot \text{Cl}$ complex was performed on human hepatocellular carcinoma (HepG-2) tumor cell line. The results evaluated upon the determination of inhibitory concentration of 50% (IC_{50}), the data was listed in Table 5. The $[\text{Sc}(\text{sulp-4})_2(\text{Cl})_2] \cdot \text{Cl}$ complex has IC_{50} equal $>1\ 000\ \mu\text{g} \cdot \text{mL}^{-1}$ for HepG-2 cell line. From this data, it is deduced that $[\text{Sc}(\text{sulp-4})_2(\text{Cl})_2] \cdot \text{Cl}$ complex has an efficient appropriate against HepG-2 cell line.

Table 4 Inhibition zone diameter of sulfa-drugs and their $\text{Sc}(\text{III})$ complexes against bacteria and fungi species

| Sample | Inhibition zone diameter ($\text{mm} \cdot \text{mg}^{-1}$ sample) | | | | | |
|----------------------------------|---|------------------------------|------------------------------------|-----------------------------------|------------------------------------|----------------------------------|
| | <i>Bacillus subtilis</i> (G+) | <i>Escherichia coli</i> (G-) | <i>Pseudomonas aeruginosa</i> (G-) | <i>Staphylococcus aureus</i> (G+) | <i>Aspergillus flavus</i> (Fungus) | <i>Candida albicans</i> (Fungus) |
| Control; DMSO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Standard | | | | | | |
| Tetracycline Antibacterial agent | 34 | 32 | 34 | 30 | — | — |
| Amphotericin B Antifungal agent | — | — | — | — | 18 | 19 |
| sulp-1 | 12 | 16 | 14 | 16 | 11 | 0.0 |
| Sc-sulp-1 | 19 | 22 | 11 | 20 | 3 | 17 |
| sulp-2 | 12 | 10 | 5 | 0.0 | 0.0 | 0.0 |
| Sc-sulp-2 | 22 | 9 | 22 | 14 | 12 | 21 |
| sulp-3 | 15 | 12 | 10 | 0.0 | 0.0 | 0.0 |
| Sc-sulp-3 | 29 | 15 | 10 | 19 | 10 | 12 |
| sulp-4 | 2 | 16 | 4 | 0.0 | 8 | 0.0 |
| Sc-sulp-4 | 10 | 22 | 9 | 20 | 2 | 19 |

Note: —G; Gram reaction; Solvent; DMSO

Table 5 Inhibitory efficiency against HepG-2 cell lines for the $[\text{Sc}(\text{sulp-4})_2(\text{Cl})_2] \cdot \text{Cl}$ complex

| Con in $\mu\text{g} \cdot \text{mL}^{-1}$ | Inhibitory activities against HepG-2 cell line | | | | | | | | | |
|---|--|-----------|-------|-----------|-------|-----------|-----------|-----------|-----------|--|
| | Ab | %C | Ab | %C | Ab | %C | Abs Av | Ave % C | SE | |
| 0 | 0.453 | 97.419 35 | 0.476 | 102.365 6 | 0.466 | 100.215 1 | 0.465 | 100 | 1.431 899 | |
| 0.1 | 0.431 | 92.688 17 | 0.415 | 89.247 31 | 0.423 | 90.772 53 | 0.423 | 90.967 74 | 0.995 42 | |
| 1 | 0.425 | 91.397 85 | 0.422 | 90.752 69 | 0.418 | 89.892 47 | 0.421 667 | 90.681 | 0.436 04 | |
| 10 | 0.418 | 89.892 47 | 0.414 | 89.032 26 | 0.417 | 89.677 42 | 0.416 333 | 89.534 05 | 0.258 462 | |
| 100 | 0.395 | 84.946 24 | 0.399 | 85.806 45 | 0.392 | 84.301 08 | 0.395 333 | 85.017 92 | 0.436 04 | |
| 1 000 | 0.257 | 55.268 82 | 0.275 | 59.139 78 | 0.266 | 57.204 3 | 0.266 | 57.204 3 | 1.117 452 | |

References

- [1] Arshia F Begum, Almandil N B, et al. *Bioorganic & Medicinal Chemistry*, 2019, 27(6): 1009.
- [2] Kausar N, Muratza S, Raza M A, et al. *Journal of Molecular Structure*, 2019, 1185: 8.
- [3] Barnhart E R (Ed.). *Physician's Desk Reference, PDR*, 43rd ed. , Medical Economics, New York, 1989.
- [4] García-Raso A, Fiol J J, Rigo S, et al. *Polyhedron*, 2000, 19: 991.
- [5] Alzuet G, Ferrer-Llugar S, Borrás J, et al. *J. Inorg. Biochem.* , 1999, 75: 189.
- [6] Scozzafava A, Menabuoni L, Mincione F, et al. *J. Med. Chem.* , 1999, 42: 2641.
- [7] Briganti F, Scozzafava A, Supuran C T. *Eur. J. Med. Chem.* , 1997, 32: 901.
- [8] Fox C L, Modak S, Stanford J W, et al. *Scand. J. Plast. Reconsr. Surg.* , 1979, 13(1): 89.
- [9] Lippincott J P. *Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry*, (8th Edn); Philadelphia, 1982. 162.
- [10] Srivastava S P, Gupta V K, Gupta K, et al. *Synth. React. Inorg. Met.-Org. Chem.* , 1987, 17(8-9): 801.
- [11] Gu S X, Deng R W, Wu J G. *Chem. J. Chin. Univ.* , 1987, 8(7): 575.
- [12] Gupta J K, Jha N K. *Ind. J. Chem.* , 1987, 26A: 529.
- [13] Kanagaraj G, Rao G N. *Ind. J. Chem.* , 1993, 32A: 594.
- [14] Abd El-Wahed M G, El-Megharbel S M, El-Sayed M Y, et al. *Bulg. Chem. Commun.* , 2015, 47(3): 895.
- [15] Koumariou E, Loktionova N S, Fellner M, et al. *Applied Radiation and Isotopes*, 2012, 70: 2669.
- [16] Bauer A W, Kirby W A, Sherris C, et al. *Am. J. Clin. Pathology*, 1996, 45: 493.
- [17] Mosmann T. *J. Immunol. Methods*, 1983, 65: 55.
- [18] Refat M S. *J. Mol. Struct.* , 2007, 842(1-3): 24.
- [19] Cotton S A. *Polyhedron*, 1999, 18: 1715.
- [20] Nakamoto K. *Infrared Spectra of Inorganic and Coordination Compounds*, Wiley Interscience, John Wiley & Sons, New York, NY, USA, 2nd edition, 1970.
- [21] Chittilappilly P S, Yusuff K K M. *Indian J. Chem.* , 2008, 47A: 848.
- [22] Dharmaraj N, Viswanathamurthi P, Natarajan K. *Trans. Met. Chem.* , 2001, 26: 105.